References
- Child J A., Crawford S M., Norfolk D R., et al. Evaluation of serum B2 microglobulin as a prognostic indicator of myelomatosis. Br J Cancer 1983; 47: 111–114
- Bataille R, Durie B GM, Grenier J. Serum beta 2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br I Haematol 1983; 55: 439–447
- Barlogie B, Alexanian R, Dixon D, et al. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338–341
- Cuzick J, Cooper E H., Mc Lennan I CM. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 1985; 52: 1–6
- Greipp P R., Katzmann J A., O'Fallon W M., et al. Impact of pre-treatment B2 microglobulin levels on survival in patients with multiple myeloma. Blood 1985; 66(Suppl. 1)638
- Bataille R, Durie B GM, Grenier J, et al. Prognostic factors and staging in multiple myeloma: a re-appraisal. J Clin Oncol 1986; 4: 80–87
- Bataille R, Grenier J, Sany J. Beta 2 microglobulin in myeloma: optical use for staging, prognosis and treatment A prospective study of 160 patients. Blood 1984; 63: 468–476
- Nilsson K, Evrin P E., Welsh K I. Production of B2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev 1974; 21: 53–84
- Durie B GM, Salmon S E. Multiple myeloma, macroglobulinaemia and monoclonal gammopathies. Recent Advances in Hae-maiology, A V. Hoffbrand, M C. Brain, J Hirsh. Churchill Livingstone, New York 1977; 243
- Pike B L., Robinson W A. Human bone marrow colony growth in agar-gel. J Cell Physiol 1970; 16: 71–81
- Hokland M, Heron I, Berg K, et al. Natural killer cell activity correlates with the amount of B2-microglobulin on human peripheral blood lymphocytes. Cell Immunol 1982; 72: 40–51
- Uchida A, Yagita M, Sugiyama H, et al. Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells. Int J Cancer 1984; 34: 375–381
- Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854
- Evrin P E., Wibell L. Serum B2-microglobulin in various disorders. Clin Chim Acta 1973; 43: 183–187
- Norfolk D, Child J A., Cooper E H., et al. Serum B2-microglobulin in myelomatosis: potential value in stratification and monitoring. Br J Cancer 1979; 39: 510–551
- Scarffe J H., Anderson H, Palmer M K., et al. Prognostic significance of pre-treatment serum B2-microglobulin levels in multiple myeloma. Eur J Cancer Clin Oncol 1983; 19: 1361–1364
- Garewal H, Durie B GM, Kyle R A., et al. Serum beta 2 microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 1984; 2: 51–57
- Brenning G, Wibell L, Bergstrom R. Serum B2-microglobulin at remission and relapse in patients with multiple myeloma. Eur J Clin Inv 1985; 15: 242–247
- Karlsson F A., Groth T, Sege K, et al. Turnover in humans of B2-microglobulin: the constant chain of HLA-antigens. Eur J Clin Inv 1980; 10: 293–300
- Salmon S E., Wampler S B. Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator. Blood 1977; 49: 379–389
- Durie B GM, Salmon S E., Mundy G R. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. B J Haematol 1981; 47: 21–30
- Nakao Y, Matsumoto H, Miyazaki T, et al. Genetic and clinical studies of serum B2-microglobuIin levels in haematological malignancies. Clin Exp Immunol 1981; 46: 134–141
- Rola-Pleszczynski M, Bolduc D, Forand S, et al. Induction of cytotoxic cell activity by peptide fragments of B2-microglobulin. Immunopharmacology 1985; 9: 39–43
- Hyafil F, Strominger J L. Dissociation and exchange of the B2-microglobulin subunit of HLA-A and HLA-B antigens. Proc Natl Acad Sci (USA) 1979; 76: 5834–5838
- Birch R E., Fanger M W., Bernier G M. B2-microglobulin enhances human lymphocyte surface receptor expression for IgG. J Immunol 1979; 122: 997–1001
- Bjorck L, Johnson U, Stoholm A G. Interaction of Clq with B2-microglobulin. Acta Pathol Microbiol Immunol Scand (Sect. C, Suppl. 284) 1984; 92: 19–23
- Fielder K, Durie B GM. Primary amyloidosis associated with multiple myeloma: predictors of successful therapy. Am J Med 1986; 80: 413–418
- Chung-Park M, Enojo P V., Hall P W. Demonstration of B2-microglobulin in the kidney by direct immunofluorescence. Vox Sang 1980; 38: 348–352
- Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as B2-microglobulin. Biochem Biophys Res Commun 1985; 129: 701–706